David E. Lazar

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Panama City
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ David E. Lazar
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David E. Lazar

Form 4 holding Director, 10%+ Owner

MINIM, INC.

Security class
Common Stock
Shares / value
2,681,980
Estimated value
$4,049,790
Report date
18 Feb 2025
Price
$1.51
Ownership
Direct
Form 4 holding Director, 10%+ Owner

MINIM, INC.

Security class
Series A Convertible Preferred Stock
Shares / value
85,910
Estimated value
$3,227,500
Report date
18 Feb 2025
Price
$1.40
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sow Good Inc.

Security class
Series AA Preferred Stock
Shares / value
1,090,000
Estimated value
$3,000,000
Report date
31 Dec 2025
Price
$2.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

TITAN PHARMACEUTICALS INC

Security class
Common Stock
Shares / value
100,000
Estimated value
$123,000
Report date
26 Jul 2023
Price
$1.23
Ownership
Direct
Form 4 holding President, Director

LQR House Inc.

Security class
Common Stock
Shares / value
100,000
Estimated value
$99,000
Report date
02 Apr 2025
Price
$0.9900
Ownership
Direct
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

OPGEN INC

Security class
Common Stock
Shares / value
100,000
Estimated value
$85,000
Report date
11 Apr 2024
Price
$0.8500
Ownership
Direct
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

OPGEN INC

Security class
Series E Convertible Preferred Stock
Shares / value
0
Estimated value
$0
Report date
30 Jul 2024
Price
$1.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Aterian, Inc.

Security class
Series AA Convertible Non-Redeemable Preferred Stock
Shares / value
1,750,000
Estimated value
Report date
27 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

MAINZ BIOMED N.V.

Security class
Series E Preferred Shares
Shares / value
1,000,000
Estimated value
Report date
22 Apr 2026
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Executive Officer, Director

KALA BIO, Inc.

Security class
Series AA Convertible Preferred Stock
Shares / value
900,000
Estimated value
Report date
24 Nov 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

Quantum Cyber N.V.

Security class
Series D Preferred Shares
Shares / value
875,300
Estimated value
Report date
05 Aug 2026
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding 10%+ Owner

Cyclacel Pharmaceuticals, Inc.

Security class
Series D Convertible Preferred Stock
Shares / value
354,738
Estimated value
Report date
26 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Indaptus Therapeutics, Inc.

Security class
Series AA Convertible Non-Redeemable Preferred Stock
Shares / value
103,200
Estimated value
Report date
23 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Cyclacel Pharmaceuticals, Inc.

Security class
Series C Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
26 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,650,000
Form 4 holding Director

Indaptus Therapeutics, Inc.

Security class
Series AAA Convertible Non-Redeemable Preferred Stock
Shares / value
0
Estimated value
Report date
23 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

KALA BIO, Inc.

Security class
Convertible Loan
Shares / value
0
Estimated value
Report date
18 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

MINIM, INC.

Security class
Warrants
Shares / value
0
Estimated value
Report date
18 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

Quantum Cyber N.V.

Security class
Series A Preferred Shares
Shares / value
0
Estimated value
Report date
05 Aug 2026
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

Quantum Cyber N.V.

Security class
Series B Preferred Shares
Shares / value
0
Estimated value
Report date
05 Aug 2026
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

Quantum Cyber N.V.

Security class
Series C Preferred Shares
Shares / value
0
Estimated value
Report date
05 Aug 2026
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by David E. Lazar

4 OPGN

OPGEN INC

Report period
30 Jul 2024
Transactions
1
Transaction value
$0
Accepted by SEC
01 Aug 2024, 17:25
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
4/A OPGN

OPGEN INC

Report period
23 Apr 2024
Transactions
1
Transaction value
+$150,000
Accepted by SEC
01 Aug 2024, 12:26
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
4 OPGN

OPGEN INC

Report period
23 Apr 2024
Transactions
1
Transaction value
+$150,000
Accepted by SEC
25 Apr 2024, 16:59
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
4 OPGN

OPGEN INC

Report period
11 Apr 2024
Transactions
1
Transaction value
$0
Accepted by SEC
12 Apr 2024, 17:03
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
4/A OPGN

OPGEN INC

Report period
05 Apr 2024
Transactions
1
Transaction value
+$200,000
Accepted by SEC
31 Jul 2024, 19:05
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
4 OPGN

OPGEN INC

Report period
05 Apr 2024
Transactions
1
Transaction value
+$200,000
Accepted by SEC
08 Apr 2024, 16:06
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
3 OPGN

OPGEN INC

Report period
25 Mar 2024
Transactions
0
Transaction value
$0
Accepted by SEC
03 Apr 2024, 09:13
Role
Chief Executive Officer, Director, 10%+ Owner
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .